

Dianthus Therapeutics Appoints Adam Veness, Esq., as General Counsel



Experienced life sciences executive brings more than a decade of public company expertise in legal, corporate governance and compliance

Dianthus Therapeutics, a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics announced the appointment of Adam Veness, Esq., as General Counsel. Joining Dianthus most recently from Cyteir Therapeutics, Veness spent much of his career as Senior Vice President, General Counsel and Secretary at Acceleron Pharma Inc. prior to the acquisition by Merck in November 2021. During his tenure at Acceleron, Veness gained experience in roles of increasing responsibility where he served on the Executive Committee responsible for company strategy, and he led all aspects of global legal and compliance, including capital markets and SEC reporting obligations, corporate governance, contracts, intellectual property, employment matters, and data privacy.

"We are excited to welcome Adam to the Dianthus team at such a pivotal time for the company," said Marino Garcia, President and Chief Executive Officer of Dianthus Therapeutics. "Adam's proven track record in helping develop and implement corporate strategy and successfully leading the legal and compliance functions in public life science companies will be invaluable as we expect to transition to a public company in the third quarter of this year. I am looking forward to working with Adam and to his contributions as we continue to build an exciting biotech company."

Prior to moving in-house to the biotechnology industry, Veness was a corporate and securities attorney at the law firm Mintz Levin where he represented and counseled public and private companies in the biopharmaceutical, technology, and healthcare industries. He began his legal career at a boutique litigation firm representing companies and individuals in a variety of civil litigation matters. Veness earned a B.A. in political science and philosophy from Tulane University, and a J.D. from Boston University School of Law.

"I am thrilled to join Dianthus as the company embarks on this exciting chapter of growth," said Adam Veness, Esq., General Counsel of Dianthus Therapeutics. "I have been impressed with the quality of the science and the caliber of the Dianthus management team, board of directors, and investors. The team's dedication to improving the lives of people with severe autoimmune disease has been inspiring, and their impressive achievements over a short period of time exemplify their sense of urgency in bringing potentially best-in-class therapies to these patients with high unmet need. I look forward to working with Marino and the entire Dianthus team as we are poised to cross the threshold into the public markets."

Source: [Dianthus Therapeutics](#)

Published on : Tue, 20 Jun 2023